Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 03 2022
Historique:
entrez: 23 3 2022
pubmed: 24 3 2022
medline: 15 4 2022
Statut: epublish

Résumé

Medication for opioid use disorder (MOUD) is the criterion standard treatment for opioid use disorder (OUD), but nationally representative studies of MOUD use in the US are lacking. To estimate MOUD use rates and identify associations between MOUD and individual characteristics among people who may have needed treatment for OUD. Cross-sectional, nationally representative study using the 2019 National Survey on Drug Use and Health in the US. Participants included community-based, noninstitutionalized adolescent and adult respondents identified as individuals who may benefit from MOUD, defined as (1) meeting criteria for a past-year OUD, (2) reporting past-year MOUD use, or (3) receiving past-year specialty treatment for opioid use in the last or current treatment episode. The main outcomes were treatment with MOUD compared with non-MOUD services and no treatment. Associations with sociodemographic characteristics (eg, age, race and ethnicity, sex, income, and urbanicity); substance use disorders; and past-year health care or criminal legal system contacts were analyzed. Multinomial logistic regression was used to compare characteristics of people receiving MOUD with those receiving non-MOUD services or no treatment. Models accounted for predisposing, enabling, and need characteristics. In the weighted sample of 2 206 169 people who may have needed OUD treatment (55.5% male; 8.0% Hispanic; 9.9% non-Hispanic Black; 74.6% non-Hispanic White; and 7.5% categorized as non-Hispanic other, with other including 2.7% Asian, 0.9% Native American or Alaska Native, 0.2% Native Hawaiian or Pacific Islander, and 3.8% multiracial), 55.1% were aged 35 years or older, 53.7% were publicly insured, 52.2% lived in a large metropolitan area, 56.8% had past-year prescription OUD, and 80.0% had 1 or more co-occurring substance use disorders (percentages are weighted). Only 27.8% of people needing OUD treatment received MOUD in the past year. Notably, no adolescents (aged 12-17 years) and only 13.2% of adults 50 years and older reported past-year MOUD use. Among adults, the likelihood of past-year MOUD receipt vs no treatment was lower for people aged 50 years and older vs 18 to 25 years (adjusted relative risk ratio [aRRR], 0.14; 95% CI, 0.05-0.41) or with middle or higher income (eg, $50 000-$74 999 vs $0-$19 999; aRRR, 0.18; 95% CI, 0.07-0.44). Compared with receiving non-MOUD services, receipt of MOUD was more likely among adults with at least some college (vs high school or less; aRRR, 2.94; 95% CI, 1.33-6.51) and less likely in small metropolitan areas (vs large metropolitan areas, aRRR, 0.41; 95% CI, 0.19-0.93). While contacts with the health care system (85.0%) and criminal legal system (60.5%) were common, most people encountering these systems did not report receiving MOUD (29.5% and 39.1%, respectively). In this cross-sectional study, MOUD uptake was low among people who could have benefited from treatment, especially adolescents and older adults. The high prevalence of health care and criminal legal system contacts suggests that there are critical gaps in care delivery or linkage and that cross-system integrated interventions are warranted.

Identifiants

pubmed: 35319762
pii: 2790432
doi: 10.1001/jamanetworkopen.2022.3821
pmc: PMC8943638
doi:

Substances chimiques

Analgesics, Opioid 0
Buprenorphine 40D3SCR4GZ

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e223821

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA045224
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA049950
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031099
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Med Care. 2020 Jul;58(7):617-624
pubmed: 32520836
J Stud Alcohol Drugs. 2019 Jul;80(4):393-402
pubmed: 31495374
J Addict Dis. 2016;35(1):22-35
pubmed: 26467975
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
JAMA. 2020 Jan 21;323(3):276-277
pubmed: 31961408
J Rural Health. 2022 Jan;38(1):87-92
pubmed: 33733547
Psychiatr Serv. 2021 Sep 1;72(9):1048-1056
pubmed: 33593105
Addiction. 2019 Mar;114(3):471-482
pubmed: 30194876
JAMA Netw Open. 2018 Jun 1;1(2):e180217
pubmed: 30646062
J Subst Abuse Treat. 2013 May-Jun;44(5):481-7
pubmed: 23265445
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
Addiction. 2021 Oct;116(10):2611-2613
pubmed: 34036659
Neurotherapeutics. 2020 Jan;17(1):55-69
pubmed: 31907876
J Subst Abuse Treat. 2020 Aug;115:108034
pubmed: 32600622
Implement Sci. 2019 May 7;14(1):48
pubmed: 31064390
Psychiatr Serv. 2011 Nov;62(11):1273-81
pubmed: 22211205
Addiction. 2020 Sep;115(9):1683-1694
pubmed: 32096302
J Subst Abuse Treat. 2021 Jul;126:108329
pubmed: 34116820
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
Addiction. 2021 Mar;116(3):677-683
pubmed: 32852864
J Subst Abuse Treat. 2013 May-Jun;44(5):473-80
pubmed: 23217610
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
JAMA Netw Open. 2020 Apr 1;3(4):e203132
pubmed: 32310285
JAMA. 2015 Oct 13;314(14):1515-7
pubmed: 26462001
J Subst Abuse Treat. 2018 Feb;85:90-96
pubmed: 28733097
J Child Adolesc Psychopharmacol. 2019 Aug;29(7):559-572
pubmed: 31009234
Health Aff (Millwood). 2020 May;39(5):747-755
pubmed: 32364847
J Health Soc Behav. 1995 Mar;36(1):1-10
pubmed: 7738325
Addiction. 2021 Oct;116(10):2615-2616
pubmed: 34184339
Drug Alcohol Depend. 2020 Jan 1;206:107654
pubmed: 31735533
JAMA Pediatr. 2017 Aug 1;171(8):747-755
pubmed: 28628701
Health Aff (Millwood). 2021 Jun;40(6):920-927
pubmed: 34097509
Drug Alcohol Depend. 2021 Apr 1;221:108627
pubmed: 33621805
Addiction. 2021 Oct;116(10):2600-2609
pubmed: 33651441
JAMA Pediatr. 2018 Nov 1;172(11):1029-1037
pubmed: 30208470
JAMA Netw Open. 2020 Feb 5;3(2):e1920843
pubmed: 32031650
JAMA Netw Open. 2020 May 1;3(5):e204996
pubmed: 32391889
J Rural Health. 2019 Jan;35(1):108-112
pubmed: 29923637
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Drug Alcohol Depend. 2017 Dec 1;181:213-218
pubmed: 29096292
JAMA. 2021 Jun 1;325(21):2206-2208
pubmed: 34061152
J Addict Med. 2018 May/Jun;12(3):170-183
pubmed: 29432333
Ann Intern Med. 2020 Jul 21;173(2):160-162
pubmed: 32311740
Psychiatr Serv. 2014 Oct;65(10):1269-72
pubmed: 25270497
JAMA. 2021 Jul 13;326(2):154-164
pubmed: 34255008
Obstet Gynecol. 2019 May;133(5):943-951
pubmed: 30969219
JAMA Netw Open. 2019 Jun 5;2(6):e196373
pubmed: 31251376
Health Aff (Millwood). 2019 Jan;38(1):14-23
pubmed: 30615514
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
Addict Behav. 2008 Jun;33(6):782-98
pubmed: 18262368
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
J Addict Med. 2015 Nov-Dec;9(6):470-7
pubmed: 26517324
J Adolesc Health. 2020 Oct;67(4):542-549
pubmed: 32336560
Epidemiology. 2007 Nov;18(6):800-4
pubmed: 18049194
Health Aff (Millwood). 2017 Dec;36(12):2046-2053
pubmed: 29200340
Subst Abus. 2018;39(4):419-425
pubmed: 29932847
Alcohol Clin Exp Res. 2021 Sep;45(9):1812-1820
pubmed: 34324221
J Subst Abuse Treat. 2020 Jul;114:108028
pubmed: 32527510
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Am J Public Health. 2022 Feb;112(2):199-201
pubmed: 35080936
Psychiatr Serv. 2017 May 1;68(5):462-469
pubmed: 28045350
J Adolesc Health. 2017 Jun;60(6):747-750
pubmed: 28258807

Auteurs

Pia M Mauro (PM)

Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.

Sarah Gutkind (S)

Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.

Erin M Annunziato (EM)

Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.

Hillary Samples (H)

Center for Health Sciences Research, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey.
Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH